Trial Profile

Combining Stellate Ganglion Block With Prolonged Exposure for PTSD: A Randomized Clinical Trial

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 07 Sep 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ropivacaine (Primary)
Indications Post-traumatic stress disorders
Focus Therapeutic Use

Most Recent Events

11 Aug 2025 Planned End Date changed from 1 Aug 2026 to 31 Aug 2027.
11 Aug 2025 Planned primary completion date changed from 1 Mar 2026 to 31 Mar 2027.
28 Feb 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com